- Original basic research
- Open Access
HPA-1 polymorphism of αIIbβ3 modulates platelet adhesion onto immobilized fibrinogen in an in-vitro flow system
© Loncar et al; licensee BioMed Central Ltd. 2007
- Received: 24 October 2006
- Accepted: 19 February 2007
- Published: 19 February 2007
Platelet adhesion and subsequent thrombus formation on a subendothelial matrix at the site of vascular damage play a crucial role in the arrest of posttraumatic bleeding but also in different pathological thrombotic events, such as acute coronary syndrome and stroke. Recently published studies have clearly demonstrated that platelet integri αIIbβ3 is intimately involved in the occlusive thrombus formation at the site of endothelial damage. Therefore, any genetic variation in the expression of this receptor may lead to an excessive bleeding or excessive thrombus formation. In this study, we evaluated the influence of HPA-1 polymorphism of integrin αIIbβ3 on platelet adhesion onto immobilized fibrinogen using an in vitro system simulating blood flow.
Platelets in anticoagulated whole blood [49 healthy previously genotyped blood donors) were labelled with fluorescence dye and perfused through a rectangular flow chamber (shear rates of 50 s-1, 500 s-1 and 1500 s-1). A fluorescence laser-scan microscope was used for visualisation and quantification of platelet adhesion at 15 sec, 1 and 5 minutes after start of perfusion.
During perfusion, the platelet adhesion linearly increased with regard to exposition time and shear rate. Perfusion of blood preincubated with Abciximab over fibrinogen-coated cover-slips showed reduced platelet adherence (absolute fluorescence: 168 ± 35 U vs. 53000 ± 19000 at control experiments, p < 0.05), as well as by perfusion over BSA-coated glass coverslips. Platelet with HPA-1a/1a genotype exhibited initial better adhesion but they also exhibited higher detachment under arterial flow conditions compared to the HPA-1b/1b platelets. Analysis of stable adhesion rate indicate that the platelets carrying the HPA-1b/1b genotype have a higher reactivity threshold for initial interaction with fibrinogen but under the higher shear rate (in regard to time of perfusion) also realize more stable bonds with fibrinogen than platelets with the HPA-1a/1a genotype.
Our data support the contention that genetically determined variants of platelet integrins αIIbβ3 could play a role in arterial thrombogenesis and thus confirm the hypothesis derived from epidemiological studies.
- Shear Rate
- Platelet Adhesion
- Relative Adhesion
- Absolute Fluorescence
A platelet-dependent process is the underlying mechanism of arterial thrombosis, and the critical role of platelets in this process is now widely accepted [1, 2]. Participation of platelets in arterial thrombosis is centered on the platelet's adhesive properties and the ability to respond to stimuli with rapid activation and, in turn, aggregation  – the same features that support the arrest of bleeding from wounds. The normal function of platelets is, however, to arrest bleeding from wounds, which requires adhesion to altered vascular surfaces and rapid cellular activation ensuring the accumulation of circulating platelets and the formation of fibrin in the growing thrombus [1–4].
There are two critical points in thrombus formation: 1) adhesion of inactivated (resting) platelets to subendothelial components such as collagen, deposed vWF or fibrinogen and 2) spreading of activated platelets with consecutive aggregation and thrombus formation. Both processes involve the platelet integrin receptors αIIbβ3. The integrin αIIbβ3 is the most abundant receptor on the platelet membrane surface, at about 80,000 copies per platelet, and is known as the receptor for fibrinogen or von Willebrand factor that mediates platelet adhesion, i.e., the formation of platelet aggregates [5–7]. This receptor is also characterized by several inheritable dimorphisms. The two most common and clinically important β3 alleles encode Leu33 (PlA1 or HPA-1a) and Pro33 (PlA2 or HPA-1b allele of the subunit β3 of the integrin αIIbβ3), with gene frequencies of 0.85 and 0.15, respectively, in the Caucasian population. Clinical studies conducted within the last ten years indicate that there could be a genetically determined predisposition for hyperaggregability which might be mediated by polymorphic receptors including integrin αIIbβ3 involved in platelet adhesion and aggregation [8–14].
Since Weiss et al.  for first time in 1996 reported that the gene frequency of the HPA-1b allele of integrin αIIbβ3 was significantly higher among young patients with myocardial infarction compared with age-matched controls, numerous clinical studies were conducted in order to define a role of related polymorphisms in arterial thrombosis. Surprisingly, these studies gave different, and in some cases, contradictory results [8, 9, 14–16].
Taking into consideration the controversy surrounding these clinical correlations, the goal of this study is to test the functional relevance of HPA-1 platelet receptor polymorphism under standardized microenvironmental conditions using a well-characterized in-vitro flow model.
The study was conducted on 49 healthy blood donors who were previously genotyped. The mean age was 42 ± 12 years, 35 (72%) were men and 14 (28%) were women. None of donors had taken any medication in the preceding 14 days. Screening parameters of hemostasis as well as factors of coagulation were within the normal range according to the international standards. Women on hormone replacement therapy and hormonal contraception, excessive smokers, obese subjects and individuals with positive familiar history related to arterial or venous disease were excluded. Since the frequency distribution of platelet glycoprotein alleles differs with regard to race, only Caucasians were included in the study. This study was performed according to the Helsinki declaration and was approved by the local ethical committee.
Venous blood obtained from the cubital vein was immediately anticoagulated with the thrombin inhibitor PPACK (D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone dihidrochloride, final concentration 40 μM, Calbiochem, San Diego Ca, USA). Platelets were labelled with a fluorescence dye mepacrine (quinacrine dihydrochloride, final concentration10 μM; Sigma Chemical, 60 min at 22°C). It immediately accumulates in the delta granules of platelets but does not influence platelet physiology . Blood was used within two hours of withdrawal. Blood anticoagulated with EDTA and 3.4% sodium citrate was immediately processed for genotyping and for assessment of screening parameters and factors of coagulation, respectively.
Determination of HPA-1 polymorphism of the β subunit of αIIbβ3
EDTA-anticoagulated blood was immediately centrifuged at 2500 rpm for 10 min at 4°C. Cells were further processed to assess genetic polymorphisms. Genomic DNA was extracted from whole blood with the QIAmp blood kit (Qiagen, Hilden, Germany). After amplification by polymerase chain reaction, genotypes were determined by allele-specific restriction enzyme analysis. Determination of the HPA-1 polymorphism of the β subunit of was performed as previously described .
Preparation of fibrinogen coated cover slips
Glass cover slips (24 × 50 mm) coated with 50 μl of fibrinogen solution (2,5 mg/ml, Sigma-Aldrich) that a sharp interface of the adhesion molecule was formed 10 mm away from the smaller edge of the cover slip . The cover slip was placed in a humid environment (60 min at 37°C) to allow the protein to adhere to the glass surface. Coated cover slips were rinsed with 10 ml of 50 mmol/l phosphate buffered saline (pH 7.35, Serag-Wiessner, Germany) to remove the non-adherent fibrinogen and placed in the flow chamber. Fibrinogen density on the glass surfaces was calculated to be 0.13 μg/mm2. For the control experiments cover slips were coated with bovine serum albumin in final concentration of 5 μg/mm2. A specificity of binding of platelets to immobilized fibrinogen was tested in experiments (n = 3) with blood preincubated with Abciximab (c7E3, Centocor, Inc; 4 μg/mL, 10 min). c7E3 Fab is a chimerical human/mouse Fab fragment derived from the murine monoclonal 7E3 antibody that binds selectively to the platelet integrin αIIbβ3.
Flow chamber, perfusion, laser-scan microscopy and data acquisition
Platelets adhesion rates onto fibrinogen and collagen-coated glass coverslips were measured in the rectangular flow chamber under linear shear rate of 50 s-1, 500 s-1 and 1500 s-1. A shear rate of 50 s-1 represents a venose system, 500 s-1 mimics a wall shear rate of larger arteries and 1500 s-1 represents a typical arteriolar shear rate as well as a shear rate by moderate arterial stenosis [2, 4].
A laser-scan microscope (Axiovert 100 M, Carl-Zeiss, Jena, Germany) allowed real-time visualisation of labelled platelets during perfusion through the chamber. To assess time-course of platelet adhesion a series of images (five images per series, 0,7 s pro image) were made at 15 sec, 1 and 5 minutes. Image analysis was performed using the ImageJ software (version 1.26t, NIH, USA). This program allows evaluation of platelet-surface interaction, consecutive aggregation and evaluation of thrombus generation within the defined area of each image. A single frame image corresponded to the area of 980 × 980 μm. The blood was perfused over fibrinogen-coated cover slips as described above. The number of stable, attached platelets on the surface was calculated as number of platelets, which remain their initial adhering position in the first and second image (time frame of 0.7 sec). Platelets were considered to move on the surface when exhibiting a spatial displacement greater than one platelet diameter. To estimate motion, a series of 5 images (time frame 0.7 sec) at one time point were made. Using ImageJ software images were binarised and a threshold was applied to distinguish platelet from background. The first two consecutive frames in a series were superimposed using the logical AND function and the resulting image represented only the overlapping areas of single platelet at two different times.
Calculations and statistics
Data in text are given as mean values ± SD. The absolute fluorescence was expressed as arbitrary units (pixel units, AU) and represents sum of fluorescence of each thrombus or individual adherent platelet in one defined area. The platelet adhesion was calculated using a logic function of the applied software (ImageJ) and represented a stable platelet adhesion between the first and second image. Taking into consideration that initial platelet adhesion and platelet detachment after initial adhesion is a dynamic process, dependent from shear rate and perfusion time data were normalized. Absolute fluorescence recorded after five minute of perfusion was divided by recorded fluorescence after 1 minute or after 15 sec of perfusion and expressed as a relative adhesion. The relative adhesion represents the increase of absolute fluorescence in function of time and reflects number of stable adherent platelet. Data normalisation allow us to evaluate stability of adherent platelets and to quantify increase of stable platelet adhesion onto immobilized fibrinogen under different shear rates in function of time.
Differences between experimental groups were tested using Student's t-test (two-sided). Regression analyses were based on individual measurements using Spearman's rank correlation coefficient. Statistical analyses were performed using SPSS for Windows, version 6.0.1. P-value of less than 0.05 (two-sided) was used to indicate a significant difference.
Clinical chemistry, haematology and haemostatic laboratory values in the blood obtained from 49 healthy blood donors were within the normal ranges. The mean age was 42 ± 12 years and did not significantly differ between male and female (41 ± 10 vs. 46 ± 12 years, p > 0.05), respectively.
During the perfusion through the rectangular chamber, the platelet adhesion linearly increased with regard to the exposition time at each tested shear rate. In 49 individual experiments, mean platelet adhesion onto fibrinogen-coated coverslips at a shear rate of 50 s-1, increased from 15 sec to 5 minutes 3.47 fold (from 3006 ± 1936 AU to 10449 ± 4850 AU), at 500 s-1 9.54-fold (from 4074 ± 1986 AU to 38900 ± 13290 AU) and at 1500 s-1 platelet adhesion increased 14.5 fold (from 3660 AU ± 1917 U to 54500 U ± 22400 AU), respectively.
A specificity of binding of platelets to immobilized fibrinogen was tested bi-directionally with two additional experimental designs. In three experiments a blood was additionally incubated with Abciximab (4 μg/ml for 10 min), c7E3 fragment, which showed a high affinity to the platelet integrin αIIbβ3. A perfusion (1500 s-1) of the preincubated blood over fibrinogen-coated cover slips omits to show significant platelet adherence (absolute fluorescence of stable adherent platelet: 168 U ± 35 U vs. 53000 U ± 19000 U at control experiments, p < 0.05). Similarly, in experiments with perfusion of labelled platelets in whole blood over BSA coated glass cover slips no significant adherence was found. The relationship between platelet adhesion and concentration of soluble plasma fibrinogen was not found (p > 0.05). Additional experiments, conducted with supplementation of soluble fibrinogen (up to 9 g/L), omitted to show any difference with regard to the untreated blood (data not present).
To test the influence of the HPA-1 polymorphism of integrin αIIbβ3 on platelet adhesion during perfusion over fibrinogen-coated coverslips blood obtained from 49 blood donors of known HPA-1 genotype (25 with HPA-1a/1a, 12 with HPA-1a1b and 12 with HPA-1b1b genotype) was used in flow experiments.
Platelet adhesion (mean ± SD) onto immobilized fibrinogen expressed as absolute fluorescence (AU) related to the platelet HPA-1 polymorphism, shear rate and perfusion time.
Shear rate and perfusion time
Platelet adhesion, AU
venose shear rate, 50 s-1
7402 ± 2542
8910 ± 2896
4947 ± 2699
10429 ± 4611
14224 ± 4718
8436 ± 4660
arterial shear rate 500 s-1
11974 ± 2494
14170 ± 5178
10520 ± 9791
40319 ± 11255
42424 ± 12344
33581 ± 18756
arterial shear rate 1500 s-1
16324 ± 5515
20474 ± 8547
10384 ± 2516
53578 ± 19251
64548 ± 32963
46154 ± 17221
After 5 min of perfusion, a significant difference between platelet adhesion activities with regard to the HPA-1 polymorphism was found only under venous flow (50 s-1) between HPA-1a/1b and HPA-1b/1b genotypes (14224 ± 4718 AU vs. 8436 ± 4660 AU, p < 0.05). Even higher platelet adhesion activity of HPA-1a/1a and HPA-1a/1b genotype compared to HPA-1b/1b genotype was also observed under arterial flow, no significant difference was observed neither at 500 s-1 nor at 1500 s-1, (p > 0.05, Table 1).
As shown, platelets with HPA-1b/1b genotype after 1 and 5 min of perfusion under arterial flow conditions reached 64% and 86% of the adhesion activity of platelets with the HPA-1a/1a genotype. This dynamic change could indicate that the platelets carrying the HPA-1b/1b genotype have a higher reactivity threshold for initial interaction fibrinogen but also under the higher shear rate (in regard to time of perfusion) also realize more stable bonds with fibrinogen than platelets with the HPA-1a/1a genotype.
To test in which order the HPA-1 polymorphism modulated stability of platelet adhesion onto immobilized fibrinogen the data were "normalized" (see Methods), and a time course of stable platelet adhesion was analyzed with regard to the shear rate and HPA-1 polymorphism.
In this study, we now provide experimental evidence that platelet adhesion to immobilized fibrinogen is modulated by platelet receptor polymorphism. This modulation is determined by the specific receptor-ligand interaction and shear rate. In this sense, we provide experimental support for the epidemiological association of the related platelet-receptor polymorphism and arterial thrombosis.
Blood from 49 subjects was collected for use in flow experiments, in order to test the influence of β-subunit polymorphism of integrin αIIbβ3 on platelet adhesion to immobilized fibrinogen. During perfusion, the shear rate expresses "dose"-response and time-response characteristics. The adherent platelets formed a single layer on fibrinogen-coated surfaces. A significant linear increase was observed in platelet adhesion as a function of time, at all shear rates. Image analysis after 1 and 5 minutes of perfusion clearly indicated that the platelets carrying the HPA-1a allele (HPA-1a/1a and HPA-1a/1b genotypes) have higher adhesion activity than platelets carrying the HPA-1b/1b genotype. This difference is continuously detectable at each shear rate applied and at each time point (Figure 1A and 1B) but quantitatively dependent on perfusion time and shear rate. These results are in agreement with the results described by Cadroy et al. . In their study conducted with non-anticoagulated blood, blood was drawn directly from volunteers' cubital veins through a parallel flow chamber. Even though the experimental design differs from ours (shear rates of 650 s-1 and 2600 s-1, perfusion time of 2 and 4 min) one common result is evident: platelets with the HPA-1a/1a genotype show higher adhesion activity than platelets with the HPA1b allele. Carlsson et al. also recently reported similar results . The results obtained in a static microtitre-plate system coated with fibrinogen indicated that the adhesion activity of platelets with the HPA-1b/1b genotype is significantly lower compared to the HPA-1a/1a genotype. Interestingly, Cadroy et al. , reported that enhanced adhesion activity of platelets with the HPA1a allele observed at 650 s-1 is abolished at shear rates of 2600 s-1. In our experiments, the adhesion activity of platelets with the HPA1a allele is constantly higher under venous flow conditions than HPA-1b/1b but varies significantly in regards to perfusion time in experiments at shear rates of 1500 s-1. After 1 and 5 min of perfusion under arterial flow conditions, platelets with HPA-1b/1b genotype reached 64% and 86% of the adhesion activity of platelets with the HPA-1a/1a genotype. This observation has initiated an assumption that platelets carrying the HPA-1b/1b genotype have a higher reactivity threshold for initial interaction of αIIbβ3 and fibrinogen but under the higher shear rate (in regard to time of perfusion) also realize more stable bonds with fibrinogen than platelets with the HPA-1a/1a genotype. To test this hypothesis and to omit some interindividual and methodical variation, data were "normalized" (see Methods), and a time course of stable platelet adhesion onto immobilized fibrinogen was analyzed with regard to the shear rate and HPA-1 polymorphism.
As shown in the Result, platelets carrying the HPA-1b/1b genotype demonstrated significantly higher stable adhesion rates between 15 sec and 5 min of perfusion than platelets carrying the HPA-1a/1a genotype (Fig. 2). Stable adhesion at a shear rate of 1500 s-1 was 1.64 times higher compared to the HPA-1a/1a genotype and reached statistical significance. A similar trend was also observed at 500 s-1, (14.45 ± 6.4 vs. 10.66 ± 5.0 for HPA-1b/1b vs. HPA-1a/1a, respectively, p = 0.07). At a venous shear rate, this enhanced effect of HPA-1b/1b genotype onto stable platelet adhesion was not observed. An analysis of the platelet adhesion rate of HPA-1b/1b genotype as a function of time (initial and late phase, see Results) showed that the observed difference was present both in the initial phase of the platelet adhesion and in the late phase (Fig. 3A and Fig. 3B).
Based on this observation, it can be concluded that the platelets with the HPA-1b/1b genotype develop stronger adhesive forces than the platelets with the HPA-1a/1a genotype. Statistically significant higher stable adhesion rates of the 1b/1b genotype could be related to the two determinants: 1) steadier platelet/solid surface interactions and 2) reduced displacement of platelets subjected to the shear stress. This results in the formation of thrombi that are more stable than the thrombi formed from HPA-1a/1a. Cadroy also indicated that clot retraction is enhanced by the involvement of platelets with the HPA-1b/1b genotype and that thrombi formed from HPA-1b/1b platelets are more resistant to thrombolysis than the thrombi formed from HPA-1a/1a platelets .
An interesting observation was made in light of the behavior of the heterozygous HPA-1a/1b genotype. According to our results, (Fig. 1A and 1B and Fig. 3A and 3B), it appears that platelets carrying "a" and "b" alleles (HPA-1a/1b) have a functional behavior similar to the HPA-1a/1a platelets. Absolute and relative adhesion are comparable with platelets that are homozygous for the "a" allele. Similar to homozygous HPA-1a/1a, our results indicated that platelets carrying the HPA-1a/1b genotype have a lower threshold for adhesion onto immobilized fibrinogen, but they are not capable of producing a stable platelet adhesion as compared to platelets with the HPA-1b/1b genotype. It may be concluded that the functional characteristic of platelets with the HPA-1a/1b genotype is predominantly determined by the "a" allele. This could explain the inconsistency of results between some epidemiological studies in which subjects with different platelet genotype were pooled (for example: HPA-1a/1a vs. HPA-1a/1b plus HPA1b/1b).
In experiments conducted under hemodynamic conditions (shear rate ranging from 25 s-1 to 125 s-1) on stabile cell lines (Chinese hamster ovary cells, CHO) with over expression of HPA-1a/1a and HPA1b/1b genotypes, Vijayan et al.  also found significant differences in the cell adhesion onto immobilized fibrinogen in regard to the β3 polymorphism. By comparing these results with the results obtained under static conditions [24, 25], the authors concluded that a thrombotic potential of respected platelet polymorphism could be underestimated when tested under static conditions. The author provided two indications for a possible explanation for significant differences in adhesion between the two tested cells lines. First, using rhodamine-phalloidin-stained actin, more F-actin was observed at the periphery of the cells with the HPA-1b/1b genotype compared with the HPA-1a/1a genotype, and second, cells with the HPA-1b/1b genotype showed a more robust reorganization of actin. The application of cytohalasin D abolished the differences in cell adhesion in regard to the HPA-1 genotype. Although the experimental design significantly differs compared to our experimental protocol, this report represents one additional experimental proof that HPA-1 polymorphism significantly modulates platelet adhesion and that this modulation is also dependent upon local hemodynamic conditions.
Platelet adhesion onto immobilized fibrinogen under arterial flow conditions is mediated by integrin αIIbβ3.
This specific interaction between immobilized fibrinogen and platelet integrin αIIbβ3 is modulated by the HPA-1 polymorphism of the β-subunit of integrin αIIbβ3.
The HPA-1b/1b genotype is associated with an increased of stable platelet adhesion.
This increased adhesion of HPA-1b/1b platelets is already evident within 1 min following the interaction of platelets with immobilized fibrinogen.
Our data support the contention that genetically determined variants of platelet integrins αIIbβ3 could play a role in arterial thrombogenesis and thus confirm the hypothesis derived from epidemiological studies. However, the risk attributable to only a single polymorphism in a complex disease such as stroke or myocardial infarction is probably low. Thus, a single polymorphism may have no clinical significance if evaluated independently, but specific combinations of common polymorphisms and the combination of related polymorphisms might play a relevant role in these diseases. In other words, the thrombotic effect of platelet receptor polymorphisms (single or combined) might be restricted to a combination with microenvironmental risk factors as demonstrated in our study. Understanding of the functional roles of platelet receptor polymorphism may increase our ability to further stratify patients according to their genetically determined thrombosis risk and may give us the opportunity to design and develop individually based therapeutic strategies in the prevention of arterial thrombosis.
This work was supported by the Deutsche Forschungsgemeinschaft, Sonderforschungsbereich 612, TP B2. Additional support was provided by the Biological Medical Research Center, Heinrich Heine University, Düsseldorf.
- Rauch U, Osende JI, Fuster V, Badimon JJ, Fayad Z, Chesebro JH: Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Ann Intern Med 2000, 134: 224-238.View ArticleGoogle Scholar
- Ruggeri ZM: Platelets in atherothrombosis. Nature Medicine 2002, 8: 1227-1234. 10.1038/nm1102-1227View ArticlePubMedGoogle Scholar
- George JN, Colman RW: Overview of platelet structure and function. In Hemostasis and Thrombosis, Basic Principles and Clinical Practice. Edited by: Colman RW, Hirsch J, Marder VJ, Clowes AW, george JN. Philadelphia, Lippincott Williams and Wilkins; 2001:381-386.Google Scholar
- Kroll MH, Hellums JD, McIntire LV, Schafer AI, Moake JL: Platelets and shear stress. Blood 1996, 88: 1525.PubMedGoogle Scholar
- Calvete JJ: Clues for understanding the structure and function of a prototypic human integrin: the platelet glycoprotein IIb/IIIa complex. Thromb Haemost 1994, 72: 1-15.PubMedGoogle Scholar
- Shattil SJ: Function and regulation of the of the β3 integrins in hemostasis and vascular biology. Thromb Haemostas 1995, 74: 149-155.Google Scholar
- Lefkovits J, Plow EF, Topol EJ: Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995, 332: 1553-1559. 10.1056/NEJM199506083322306View ArticlePubMedGoogle Scholar
- Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ: A Polymorphism of a Platelet Glycoprotein Receptor as an Inherited Risk Factor for Coronary Thrombosis. N Engl J Med 1996, 334: 1090-1094. 10.1056/NEJM199604253341703View ArticlePubMedGoogle Scholar
- Zotz RB, Winkelmann BR, Nauck M, Giers G, Maruhn-Debowski B, Marz W, Scharf RE: Polymorphism of platelet membrane glycoprotein IIIa: human platelet antigen 1b (HPA-1b/PlA2) is an inherited risk factor for premature myocardial infarction in coronary artery disease. Thromb Haemost 1998, 79: 731-735.PubMedGoogle Scholar
- Clemetson KJ: Platelet receptors for adhesion and activation. Variability as a factor in susceptibility to cardiovascular diseases. Ital Heart J 2001, 2: 816-8.PubMedGoogle Scholar
- Santoso S, Kunicki T: Platelet receptor polymorphisms and thrombotic risk. Ital heart J 2001, 2: 811-815.PubMedGoogle Scholar
- Corral J, Gonzalez-Conejero R, Vicente V: Genetic determinants of platelet function in thromboembolic diseases. J Biol Regul Homeost Agents 2004, 18: 166-171.PubMedGoogle Scholar
- Meisel C, Lopez JA, Stangl K: Role of platelet glycoprotein polymorphisms in cardiovascular diseases. Naunyn Schmiedebergs Arch Pharmacol 2004, 369: 38-54. 10.1007/s00210-003-0828-yView ArticlePubMedGoogle Scholar
- Zotz RB, Winkelmann BR, Muller C, Boehm BO, Marz W, Scharf RE: Association of polymorphisms of platelet membrane integrins alpha IIb(beta)3 (HPA-1b/Pl) and alpha2(beta)1 (alpha807TT) with premature myocardial infarction. J Thromb Haemost 2005, 3: 1522-1529. 10.1111/j.1538-7836.2005.01432.xView ArticlePubMedGoogle Scholar
- Streifler JY, Rosenberg N, Chetrit A, Eskaraev R, Sela A, Dardik R, Zivelin A, Ravid B, Davidson J, Seligsohn U, Inbal A: Cerebrovascular events in patients with significant stenosis of the carotid artery are associated with hyperhomocysteinemia and platelet antigen-1(Leu33Pro) polymorphism. Stroke 2001, 32: 2753-2758.View ArticlePubMedGoogle Scholar
- Cole VJ, Staton JM, Eikelboom JW, Hankey GJ, Yi Q, Shen Y, Berndt MC, Baker RI: Collagen platelet receptor polymorphisms integrin alpha2beta1 C807T and GPVI Q317L and risk of ischemic stroke. J Thromb Haemost 2003, 1: 963-70. 10.1046/j.1538-7836.2003.00179.xView ArticlePubMedGoogle Scholar
- Savage B, Saldivar E, Ruggeri ZM: Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996, 84: 289-297. 10.1016/S0092-8674(00)80983-6View ArticlePubMedGoogle Scholar
- Unkelbach K, Kalb R, Santoso S, Kroll H, Mueller-Eckhardt C, Kiefel V: Genomic RFLP typing of human platelet alloantigens Zw(PlA), Ko, Bak and Br (HPA-1, 2, 3, 5). Br J Haematol 1995, 89: 169-176.View ArticlePubMedGoogle Scholar
- Tsuji S, Sugimoto M, Miyata S, Kuwahara M, Kinoshita S, Yoshioka A: Real-time analysis of mural thrombus formation in various platelet aggregation disorders: distinct shear-dependent roles of platelet receptors and adhesive proteins under flow. Blood 1999, 94: 968-975.PubMedGoogle Scholar
- Cadroy Y, Sakariassen KS, Charlet JP, Thalamas C, Boneu B, Sie P: Role of 4 platelet membrane glycoprotein polymorphisms on experimental arterial thrombus formation in men. Blood 2001, 98: 3159-3161. 10.1182/blood.V98.10.3159View ArticlePubMedGoogle Scholar
- Carlsson LE, Großjohann B, Freier J, Santoso S, Greinacher A: A platelet adhesion in a microtitar plate system applicable for assessment of differences in platelet adhesion associated with the GPIIb/IIIa and GP Ia/IIa polymorphism. Transfus Med Hemother 2003, (Supplement 1):25-25.Google Scholar
- Cadroy Y, Sakariassen K, Grandjean H, Thalamas C, Boneu B, Sie P: The effect of platelet PlA polymorphism on experimental thrombus formation in man depends on blood flow and thrombogenic substrate. Thromb Haemost 2001, 85: 1097-1103.PubMedGoogle Scholar
- Vijayan KV, Huang TC, Liu Y, Bernardo A, Dong JF, Goldschmidt-Clermont PJ, Alevriadou BR, Bray PF: Shear stress augments the enhanced adhesive phenotype of cells expressing the Pro33 isoform of integrin beta3. FEBS Lett 2003, 540: 41-6. 10.1016/S0014-5793(03)00170-4View ArticlePubMedGoogle Scholar
- Vijayan KV, Goldschmidt-Clermont PJ, Roos C, Bray PF: The Pl(A2) polymorphism of integrin beta(3) enhances outside-in signaling and adhesive functions. J Clin Invest 2000, 105: 793-802.PubMed CentralView ArticlePubMedGoogle Scholar
- Vijayan KV, Liu Y, Dong JF, Bray PF: Enhanced activation of mitogen-activated protein kinase and myosin light chain kinase by the Pro33 polymorphism of integrin beta 3. J Biol Chem 2003, 278: 3860-3867. 10.1074/jbc.M208680200View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.